Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05091866 · ClinicalTrials.gov registry record · Early Phase 1
Natural Progesterone for the Treatment of Recurrent Glioblastoma
A Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma, sponsored by Emory University.
- Active
- Registry status
- Early Phase 1
- Development phase
- 4
- Enrollment target
- 1
- Study location
NCT05091866: Active Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma, sponsored by Emory University.
NCT05091866 is a Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma that is active but no longer recruiting, run by Emory University. The registered enrollment target is 4 participants, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05091866, a Early Phase 1 study of Recurrent Glioblastoma and Gliosarcoma, is active but no longer recruiting, sponsored by Emory University.
- ACTIVE NOT RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 4 participants
- Enrollment target
- 1
- Study location
Study Summary
This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progesterone may help control tumor growth and spread in patients with glioblastoma.
Primary Outcome
This analysis will be performed to determine what plasma drug levels can be achieved in recurrent glioblastoma (GBM) patients with subcutaneous administration of natural progesterone and whether this is in line with what was previously determined in healthy subjects.
Conditions Studied
Interventions
- OTHER Quality-of-Life Assessment
- OTHER Questionnaire Administration
- BIOLOGICAL Therapeutic Progesterone
Study Locations (1)
Georgia
- Emory University Hospital/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2022-04-11 |
| Est. Completion | 2027-04-01 |
| Phase | Early Phase 1 |
What the registry record for NCT05091866 still lists
NCT05091866 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 4 participants, a relatively small participant target, below the 69-participant average among 62 other Recurrent Glioblastoma trials with a reported enrollment target (94% lower).
The record links to 2 conditions, with Recurrent Glioblastoma appearing as the primary indexed condition, and to 3 interventions - of which Quality-of-Life Assessment is the first listed.
NCT05091866 reports a single indexed study location in Georgia.
Frequently Asked Questions
What is clinical trial NCT05091866 about?
NCT05091866 is a clinical study titled "Natural Progesterone for the Treatment of Recurrent Glioblastoma". This early phase I trial identifies the best dose, possible benefits and/or side effects of natural progesterone in treating patients with glioblastoma that has come back (recurrent). Progesterone is a type of hormone made by the body that plays a role in the menstrual cycle and pregnancy. Progester...
What is the current status of trial NCT05091866?
This trial is currently active not recruiting. It is a Early Phase 1 study. The enrollment target is 4 participants. The study started on 2022-04-11. Estimated completion is 2027-04-01.
What conditions does trial NCT05091866 study?
This clinical trial studies the following conditions: Recurrent Glioblastoma, Gliosarcoma.
What interventions are being tested in trial NCT05091866?
The interventions under investigation include: Quality-of-Life Assessment (OTHER), Questionnaire Administration (OTHER), Therapeutic Progesterone (BIOLOGICAL).
Who is sponsoring clinical trial NCT05091866?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05091866 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Glioblastoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05091866's enrollment target sits among peer trials
4 63rd of 62 the lowest of 62 other Recurrent Glioblastoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Recurrent Glioblastoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sonodynamic Therapy With SONALA-001 or 5-ALA HCL and Magnetic Resonance Guided Focused Ultrasound for the Treatment of Progressive or Recurrent Glioblastoma
RECRUITING · Early Phase 1
-
A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma
RECRUITING · Early Phase 1
-
Multitracer [18F]Fluciclovine and 18F-FDG PET, and Advanced MRI for Metabolic Profiling of Glioblastoma
RECRUITING · Early Phase 1
-
Identification of Treatment Concentrations of Defactinib or VS-6766 for the Treatment of Patients With Glioblastoma
ACTIVE NOT RECRUITING · Early Phase 1
-
Fimepinostat in Treating Brain Tumors in Children and Young Adults
ACTIVE NOT RECRUITING · Early Phase 1
-
CARv3-TEAM-E T Cells in Glioblastoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI